Pathophysiology of Vasculitis

Vascular Medicine: A Companion to Braunwald's Heart Disease: Second Edition

Volumn , Issue , 2013, Pages 126-132

  Libby, Peter ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84924587185     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-2930-6.00009-4     Document Type: Chapter

References (41)

1. Watts R., Lane S., Hanslik T., et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007, 66(2):222-227.
2. Watts R.A., Suppiah R., Merkel P.A., et al. Systemic vasculitis--is it time to reclassify?. Rheumatology (Oxford) 2010.
3. Basu N., Watts R., Bajema I., et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis 2010, 69(10):1744-1750.
4. Jennette J.C, Xiao H., Falk R., et al. Experimental models of vasculitis and glomerulonephritis induced by antineutrophil cytoplasmic autoantibodies. Contrib Nephrol 2011, 169:211-220.
5. Bautz D.J., Preston G.A., Lionaki S., et al. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol 2008, 19(12):2421-2429.
6. Chen M., Kallenberg C.G. New advances in the pathogenesis of ANCA-associated vasculitides. Clin Exp Rheumatol 2009, 27(1 Suppl 52):S108-S114.
7. Kessenbrock K., Krumbholz M., Schonermarck U., et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009, 15(6):623-625.
8. Preston G.A., Yang J.J., Xiao H., et al. Understanding the pathogenesis of ANCA: where are we today?. Cleve Clin J Med 2002, 69(Suppl 2):SII51-SII54.
9. Jennette J.C., Xiao H., Falk R.J. Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 2006, 17(5):1235-1242.
10. Franssen C.F., Stegeman C.A., Kallenberg C.G, et al. Antiproteinase 3- and vasculitis. Kidney Int 2000, 57(6):2195-2206.
11. Sugiyama S., Kugiyama K., Aikawa M., et al. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol 2004, 24(7):1309-1314.
12. Kain R., Exner M., Brandes R., et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008, 14(10):1088-1096.
13. Wilde B., Thewissen M., Damoiseaux J., et al. T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells?. Arthritis Res Ther 2010, 12(1):204.
14. Xiao H., Heeringa P., Hu P., et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002, 110(7):955-963.
15. Xiao H., Heeringa P., Liu Z., et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol 2005, 167(1):39-45.
16. Schreiber A., Xiao H., Falk R.J, et al. Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. J Am Soc Nephrol 2006, 17(12):3355-3364.
17. Pfister H., Ollert M., Frohlich L.F., et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 2004, 104(5):1411-1418.
18. Nolan S.L., Kalia N., Nash G.B., et al. Mechanisms of ANCA-mediated leukocyte-endothelial cell interactions in vivo. J Am Soc Nephrol 2008, 19(5):973-984.
19. Little M.A., Savage C.O. The role of the endothelium in systemic small vessel vasculitis. Clin Exp Rheumatol 2008, 26(3 Suppl 49):S135-S140.
20. Guilpain P., Servettaz A., Goulvestre C., et al. Pathogenic effects of antimyeloperoxidase antibodies in patients with microscopic polyangiitis. Arthritis Rheum 2007, 56(7):2455-2463.
21. Hattar K., Sibelius U., Bickenbach A., et al. Subthreshold concentrations of anti-proteinase 3 antibodies (c-ANCA) specifically prime human neutrophils for fMLP-induced leukotriene synthesis and chemotaxis. J Leukoc Biol 2001, 69(1):89-97.
22. Mueller A., Holl-Ulrich K., Feller A.C, et al. Immune phenomena in localized and generalized Wegener's granulomatosis. Clin Exp Rheumatol 2003, 21(6 Suppl 32):S49-S54.
23. Tervaert J.W. Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis. Clin Exp Immunol 2009, 156(3):377-385.
24. Voswinkel J., Muller A., Lamprecht P. Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production. Ann N Y Acad Sci 2005, 1051:12-19.
25. Muschen M., Warskulat U., Perniok A., et al. Involvement of soluble CD95 in Churg-Strauss syndrome. Am J Pathol 1999, 155(3):915-925.
26. Hellmich B., Ehlers S., Csernok E., et al. Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 2003, 21(6 Suppl 32):S69-S77.
27. Lamprecht P., Gutzeit O., Csernok E., et al. Prevalence of ANCA in mixed cryoglobulinemia and chronic hepatitis C virus infection. Clin Exp Rheumatol 2003, 21(6 Suppl 32):S89-S94.
28. Pendergraft W.F., Pressler B.M., Jennette J.C., et al. Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease. J Mol Med 2005, 83(1):12-25.
29. Pendergraft W.F., Alcorta D.A., Segelmark M., et al. ANCA antigens, proteinase 3 and myeloperoxidase, are not expressed in endothelial cells. Kidney Int 2000, 57(5):1981-1990.
30. Seko Y. Giant cell and Takayasu arteritis. Curr Opin Rheumatol 2007, 19(1):39-43.
31. Chauhan S.K., Singh M., Nityanand S. Reactivity of gamma/delta T cells to human 60-kd heat-shock protein and their cytotoxicity to aortic endothelial cells in Takayasu arteritis. Arthritis Rheum 2007, 56(8):2798-2802.
32. Chauhan S.K., Tripathy N.K., Nityanand S. Antigenic targets and pathogenicity of anti-aortic endothelial cell antibodies in Takayasu arteritis. Arthritis Rheum 2006, 54(7):2326-2333.
33. Brack A., Geisler A., Martinez-Taboada V.M., et al. Giant cell vasculitis is a T cell-dependent disease. Mol Med 1997, 3(8):530-543.
34. Deng J., Younge B.R., Olshen R.A., et al. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010, 121(7):906-915.
35. Nagano H., Mitchell R.N., Taylor M.K., et al. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest 1997, 100(3):550-557.
36. Tellides G., Tereb D.A., Kirkiles-Smith N.C., et al. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature 2000, 403(6766):207-211.
37. Dal Canto A.J., Swanson P.E., O'Guin A.K., et al. IFN-gamma action in the media of the great elastic arteries, a novel immunoprivileged site. J Clin Invest 2001, 107(2):R15-R22.
38. Amento E.P., Ehsani N., Palmer H., et al. Cytokines and growth factors positively and negatively regulate intersitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1991, 11:1223-1230.
39. Raines E., Rosenfeld M., Libby P. The role of macrophages. Atherothrombosis and coronary artery disease 2004, 505-520. Lippincott Williams & Wilkins, Philadelphia. ed 2,. V. Fuster, E.J. Topol, E.G. Nabel (Eds.).
40. Jones R.B., Tervaert J.W., Hauser T., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363(3):211-220.
41. JCS Joint Working Group Guideline for Management of Vasculitis Syndrome (JCS 2008). Circ J 2011, 75(2):474-503.